Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
One Percent Rule Checklist For Safer Forex Trading Risk 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
Tesla Revives Dojo Supercomputer Project With AI5 Chip at the Core 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
MALVERN, Pa., April 24, 2017 -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biotechnology company focused on defining new standards of care in medical and aesthetic dermatology, today announced it will sponsor a symposium on Janus Kinase (JAK) inhibitors at the 76th Annual Society for Investigative Dermatology Meeting in Portland, Oregon. The symposium, titled “You Don’t Know JAK,” will be held on Thursday, April 27, 2017, from 12:00-1:45 PM PST. Poster presentations include:
- Clinical investigation of JAK inhibitor tofacitinib in scarring alopecias: Lindsey Bordone, MD, Columbia University, New York, NY, Abstract #075
- Treatment of vitiligo with topical Janus Kinase inhibitor ruxolitinib: Brooke Rothstein, Tufts Medical Center, Boston, MA, Abstract #770
- Predictive modeling of drug response and mechanism of action in alopecia areata clinical trials: James Chen, PhD, Columbia University, New York, NY, Abstract #397
Dr. Neal Walker, President and Chief Executive Officer, and Dr. Stuart Shanler, Chief Scientific Officer, will be in attendance. Following the poster presentations, there will be a panel discussion and question and answer session with presenters.
Additional information on the 76th Annual Society of Investigative Dermatology Meeting can be found at: http://www.sidnet.org/news/339026/View-the-2017-Annual-Meeting-Program.htm
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a dermatologist-led biotechnology company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. Aclaris is based in Malvern, Pennsylvania.
Contact: Aclaris Contact Michael Tung, M.D. Investor Relations 484-329-2140 [email protected] Media Contact Mariann Caprino TogoRun 917-242-1087 [email protected]
